{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 38 of 51', 'Study ID RCB: 2020-A00652-37', 'Objective', 'Statistical analysis', 'Exposure measure', 'Outcome measure', 'Covariables', '2.a', 'Proportions', 'N/A', 'Achievement of the', 'N/A', 'main goal (yes/no) at', '12/16 weeks', '2.b', 'Proportions -', 'N/A', 'Achievement of the', 'N/A', 'sensitivity analysis', 'main goal (yes/no) at', '12/16 weeks', '2.c', 'Binary logistic', 'N/A', 'Achievement of the', 'Relevant', 'regression models,', 'main goal (yes/no) at', 'confounders (eg :', '12/16 weeks', 'demographic data,', 'medical history,', 'previous treatment...)', '2.d', 'Proportions', 'N/A', 'Achievement of the', 'N/A', 'main goal (yes/no) at', '12/16 weeks for each', 'component', '3.a', 'Means', 'N/A', 'Description and', 'N/A', 'evolution of PASI', 'score at 12/16 then', '52 4 weeks', '3.b', 'Mixed effect model', 'N/A', 'Evolution of PASI', 'PASI score at baseline', 'with repeated', 'score over the 52 + 4', 'measurement', 'weeks', '3.c', 'Means', 'N/A', 'Description and', 'N/A', 'evolution of DLQI', 'score at 12/16 then', '52 4 weeks', '3.d', 'Mixed effect model', 'N/A', 'Evolution of DLQI', 'DLQI score at', 'with repeated', 'score over the 52 4', 'baseline', 'measurement', 'weeks', '3.e', 'Proportions.', 'N/A', 'PASI>90 versus', 'Khi-Square analysis', 'satisfaction level', '(QoL Component', 'grid)', '4.a', 'Proportions', 'N/A', 'Proportion of', 'N/A', 'concordant choices', '(yes/no)', '4.b', 'Kappa coefficient', 'N/A', 'Agreement for the', 'N/A', 'selected dimension', 'between patient and', 'physician', '5.a', 'Proportions', 'N/A', 'Maintenance of the', 'N/A', 'main goal (yes/no) at', '52 4 weeks', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 39 of 51', 'Study ID RCB: 2020-A00652-37', 'Objective', 'Statistical analysis', 'Exposure measure', 'Outcome measure', 'Covariables', '6.a', 'Proportions', 'N/A', 'Change of the', 'N/A', 'therapeutic objective', 'yes/no) at 12/16', 'weeks', '9.8.6 Safety analysis', 'Study AEs will be tabulated in the final report. AEs will be classified by system organ class', '(SOC), preferred terms (PT) in accordance with the current version of the Medical dictionary', 'for Regulatory Activities (MedDRA), causality and seriousness.', 'Safety analyses will be performed on the Safety population.', '9.9 Quality Control', 'LEO Pharma and/or its designee will monitor study data to ensure data quality and', 'conformance to Good Clinical Practices (GCPs). Verification of Case Report Form (CRF) data to', 'source documentation, assessment of study progress and assessment of Investigator', 'compliance to study protocol and Ethics Committee/IRB requirements will be performed', 'according to a pre-defined monitoring plan.', '9.9.1 Data Collection', 'Data will be collected on printed CRFs by the investigators. The completed CRFs as well as the', 'completed questionnaires will be sent to the CRO and entered by a data manager into a', 'computer database developed specifically for this study.', 'Data will remain anonymous.', 'Access to the database will be restricted to personnel responsible for data entry and to data', 'management and statistics personnel who are directly involved in the management or analysis', 'of this study. Investigators will not have access to the computer database.', '9.9.2 Data monitoring', 'The Monitoring Plan is a separate document, in which detailed monitoring arrangements such', 'monitoring frequency, timing of monitoring visit, access to source data etc. are defined.', 'The level of source data verification will be set in the Monitoring Plan.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}